Alembic Pharmaceuticals Ltd vs Concord Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 754.5 as of 30 Apr 15:30 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 47.2 on March 2025 . This represents a CAGR of -4.45% over 2 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 17537 crore on March 2025 . This represents a CAGR of 4.95% over 2 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Concord Biotech Ltd for the Dec '25 is ₹ 287.74 crore as compare to the Sep '25 revenue of ₹ 262.7 crore. This represent the growth of 9.53% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Concord Biotech Ltd for the Dec '25 is ₹ 104.98 crore as compare to the Sep '25 ebitda of ₹ 104.13 crore. This represent the growth of 0.82% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Concord Biotech Ltd changed from ₹ 59.59 crore to ₹ 63.64 crore over 7 quarters. This represents a CAGR of 3.83% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Concord Biotech Ltd changed from 2.73 % on March 2022 to 24.54 % on March 2025 . This represents a CAGR of 73.15% over 4 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Concord Biotech Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Concord Biotech Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,830 Cr while Market cap of Concord Biotech Ltd is 11,927 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Concord Biotech Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Concord Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Concord Biotech Ltd?

As of May 3, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹754.5. On the other hand, Concord Biotech Ltd stock price is INR ₹1140.15.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Concord Biotech Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Concord Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.